MedTrace Logo

Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System

NCT06745011 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-01-08

No results posted yet for this study

Summary

Description of a method to detect Parkinson's disease or Parkinson's-like disease at an early stage (Prodromal Parkinson's Disease) where damage is still confined to the peripheral nervous system damage. Simultaneous collection of biological material to establish a biobank for use as prognostic biomarkers for the development of Parkinson's disease and other neurodegenerative diseases in which pathological alpha-synuclein deposits accumulate.

Conditions

  • Polyneuropathy
  • Alpha-Synucleinopathy
  • Lewy Body Disease
  • Parkinson Disease (PD)
  • Lewy Body Dementia (LBD)
  • Multiple System Atrophy
  • Autonomic Failure
  • Cardiac Imaging
  • Rapid Eye Movement Sleep Behavior Disorder
  • REM Sleep Behavior Disorder (iRBD)
  • REM Behavior Disorder

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Astrid J. Terkelsen, MD, DrMedSc, PhD, Professor · Department of clinical medicine, Aarhus University and Department of Neurology, Aarhus University Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-13
Primary Completion
2031-05-01
Completion
2031-05-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06745011 on ClinicalTrials.gov